ovarian adnexal mass
Aspira Q4 Revenues up 36 Percent
The company reported total revenues of $1.9 million, up from $1.4 million in Q4 2020, while sales of its OVA1plus test were up 23 percent.
Aspira Women's Health Preliminary Q4 OVA1 Sales up 23 Percent; Firm Details Pipeline Progess
The company also announced a five-year deal with healthcare group Axia Women's Health to provide in-house genetic carrier screening.
Aspira Q4 Revenues Up 11 Percent, Firm Inks Deal for Ovarian Cancer Detection Tech
The agreement is with the Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz.
The glycoproteomics firm is using its mass spec platform for ovarian cancer and immunotherapy tests as well as service work for pharma and other partners.
Aspira Eyes $11M in Private Equity Financing
Investors in the company, formerly known as Vermillion, have agreed to purchase $11 million in unregistered common stock at a price of $3.50 per share.
Mar 29, 2017
Vermillion Q4 Revenues Up 123 Percent
Nov 10, 2016
Vermillion Q3 Revenues Up 89 Percent
Aug 19, 2016
May 16, 2016
Vermillion Q1 Revenues Down 47 Percent
Mar 24, 2016
Mar 21, 2016
Vermillion Receives FDA 510(k) Clearance for Overa
Jan 22, 2016
Dec 1, 2015
Vermillion Wins Medi-Cal Coverage for OVA1
Nov 20, 2015
Nov 12, 2015
Vermillion Q3 Revenues Up 2 Percent
Oct 30, 2015
Oct 26, 2015